Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis

Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis

Abstract Background Docetaxel, pemetrexed, erlotinib, and gefitinib are recommended as second-line treatment for advanced non-small cell lung cancer (NSCLC) with wild-type or unknown status for epidermal growth factor receptor (EGFR). However, the number of published randomized clinical trials (RCTs...

Full description

Bibliographic Details
Main Authors: Perrine Créquit, Anna Chaimani, Amélie Yavchitz, Nassima Attiche, Jacques Cadranel, Ludovic Trinquart, Philippe Ravaud
Format: Article
Language:English
Published: BMC 2017-10-01
Series:BMC Medicine
Subjects:
Systematic review
Comparative effectiveness review
NSCLC
Immunotherapy
Treatments
Wild-type EGFR
Online Access:http://link.springer.com/article/10.1186/s12916-017-0954-x

Internet

http://link.springer.com/article/10.1186/s12916-017-0954-x

Similar Items